Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer

Bergenfelz, Caroline LU orcid ; Roxå, Anna ; Mehmeti, Meliha LU ; Leandersson, Karin LU orcid and Larsson, Anna Maria LU (2020) In Cancer Immunology, Immunotherapy 69(3). p.435-448
Abstract

The overall aim of this prospective study was to delineate the role of monocytic myeloid-derived suppressor cells (Mo-MDSCs) in patients with metastatic breast cancer (MBC). MDSCs are a heterogeneous group of immunosuppressive cells often enriched in different malignancies which hold prognostic and predictive value for clinical outcomes. Here, we assessed the clinical significance of Mo-MDSCs in 54 patients with de novo or distant recurrent MBC. We show that high levels of Mo-MDSCs significantly correlated with de novo MBC (metastatic disease at initial diagnosis), estrogen receptor (ER) negativity, and liver- and bone metastasis. A trend towards an association between high levels of Mo-MDSCs and survival (P = 0.053) was also found in... (More)

The overall aim of this prospective study was to delineate the role of monocytic myeloid-derived suppressor cells (Mo-MDSCs) in patients with metastatic breast cancer (MBC). MDSCs are a heterogeneous group of immunosuppressive cells often enriched in different malignancies which hold prognostic and predictive value for clinical outcomes. Here, we assessed the clinical significance of Mo-MDSCs in 54 patients with de novo or distant recurrent MBC. We show that high levels of Mo-MDSCs significantly correlated with de novo MBC (metastatic disease at initial diagnosis), estrogen receptor (ER) negativity, and liver- and bone metastasis. A trend towards an association between high levels of Mo-MDSCs and survival (P = 0.053) was also found in patients with distant recurrent ER-positive MBC. We therefore propose that an increased population of Mo-MDSCs may be related to the metastatic or immunoregulatory switch associated with transition to a more systemic disease. Our data imply that high levels of systemic Mo-MDSCs represent patients with more aggressive disease and worse outcome.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Breast cancer, Estrogen receptor, Metastasis, Mo-MDSCs, Survival
in
Cancer Immunology, Immunotherapy
volume
69
issue
3
pages
14 pages
publisher
Springer
external identifiers
  • scopus:85077708211
  • pmid:31925475
ISSN
0340-7004
DOI
10.1007/s00262-019-02472-z
language
English
LU publication?
yes
id
6a1ee857-dd97-4869-a0fa-8f6d69b86aae
date added to LUP
2020-01-28 08:55:56
date last changed
2025-10-17 16:24:00
@article{6a1ee857-dd97-4869-a0fa-8f6d69b86aae,
  abstract     = {{<p>The overall aim of this prospective study was to delineate the role of monocytic myeloid-derived suppressor cells (Mo-MDSCs) in patients with metastatic breast cancer (MBC). MDSCs are a heterogeneous group of immunosuppressive cells often enriched in different malignancies which hold prognostic and predictive value for clinical outcomes. Here, we assessed the clinical significance of Mo-MDSCs in 54 patients with de novo or distant recurrent MBC. We show that high levels of Mo-MDSCs significantly correlated with de novo MBC (metastatic disease at initial diagnosis), estrogen receptor (ER) negativity, and liver- and bone metastasis. A trend towards an association between high levels of Mo-MDSCs and survival (P = 0.053) was also found in patients with distant recurrent ER-positive MBC. We therefore propose that an increased population of Mo-MDSCs may be related to the metastatic or immunoregulatory switch associated with transition to a more systemic disease. Our data imply that high levels of systemic Mo-MDSCs represent patients with more aggressive disease and worse outcome.</p>}},
  author       = {{Bergenfelz, Caroline and Roxå, Anna and Mehmeti, Meliha and Leandersson, Karin and Larsson, Anna Maria}},
  issn         = {{0340-7004}},
  keywords     = {{Breast cancer; Estrogen receptor; Metastasis; Mo-MDSCs; Survival}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{435--448}},
  publisher    = {{Springer}},
  series       = {{Cancer Immunology, Immunotherapy}},
  title        = {{Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer}},
  url          = {{http://dx.doi.org/10.1007/s00262-019-02472-z}},
  doi          = {{10.1007/s00262-019-02472-z}},
  volume       = {{69}},
  year         = {{2020}},
}